These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 15523695)

  • 1. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase.
    Wang FQ; So J; Reierstad S; Fishman DA
    Int J Cancer; 2005 Mar; 114(1):19-31. PubMed ID: 15523695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases.
    Wang FQ; So J; Reierstad S; Fishman DA
    Int J Cancer; 2006 Feb; 118(4):879-88. PubMed ID: 16152587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion.
    Wang FQ; Smicun Y; Calluzzo N; Fishman DA
    Mol Cancer Res; 2006 Nov; 4(11):831-41. PubMed ID: 17114341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.
    Paju A; Sorsa T; Tervahartiala T; Koivunen E; Haglund C; Leminen A; Wahlström T; Salo T; Stenman UH
    Br J Cancer; 2001 May; 84(10):1363-71. PubMed ID: 11355948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate.
    Itoh Y; Binner S; Nagase H
    Biochem J; 1995 Jun; 308 ( Pt 2)(Pt 2):645-51. PubMed ID: 7772054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases.
    Sato T; Sakai T; Noguchi Y; Takita M; Hirakawa S; Ito A
    Gynecol Oncol; 2004 Jan; 92(1):47-56. PubMed ID: 14751137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analyses.
    Fujimoto N; Ward RV; Shinya T; Iwata K; Yamashita K; Hayakawa T
    Biochem J; 1996 Feb; 313 ( Pt 3)(Pt 3):827-33. PubMed ID: 8611162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts.
    Boyd RS; Balkwill FR
    Br J Cancer; 1999 May; 80(3-4):315-21. PubMed ID: 10408832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).
    Worley JR; Thompkins PB; Lee MH; Hutton M; Soloway P; Edwards DR; Murphy G; Knäuper V
    Biochem J; 2003 Jun; 372(Pt 3):799-809. PubMed ID: 12630911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis(2-oxopropyl)amine.
    Iki K; Tsutsumi M; Kido A; Sakitani H; Takahama M; Yoshimoto M; Motoyama M; Tatsumi K; Tsunoda T; Konishi Y
    Carcinogenesis; 1999 Jul; 20(7):1323-9. PubMed ID: 10383907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma.
    Nakada M; Kita D; Futami K; Yamashita J; Fujimoto N; Sato H; Okada Y
    J Neurosurg; 2001 Mar; 94(3):464-73. PubMed ID: 11235952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin.
    von Bredow DC; Cress AE; Howard EW; Bowden GT; Nagle RB
    Biochem J; 1998 May; 331 ( Pt 3)(Pt 3):965-72. PubMed ID: 9560329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane-type 1 matrix metalloproteinase-mediated progelatinase A activation in non-tumorigenic and tumorigenic human keratinocytes.
    Baumann P; Zigrino P; Mauch C; Breitkreutz D; Nischt R
    Br J Cancer; 2000 Nov; 83(10):1387-93. PubMed ID: 11044366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases.
    Nakamura H; Fujii Y; Ohuchi E; Yamamoto E; Okada Y
    Eur J Biochem; 1998 Apr; 253(1):67-75. PubMed ID: 9578462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3.
    Will H; Atkinson SJ; Butler GS; Smith B; Murphy G
    J Biol Chem; 1996 Jul; 271(29):17119-23. PubMed ID: 8663332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases.
    Ogata Y; Itoh Y; Nagase H
    J Biol Chem; 1995 Aug; 270(31):18506-11. PubMed ID: 7629179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
    So J; Wang FQ; Navari J; Schreher J; Fishman DA
    Gynecol Oncol; 2005 Jun; 97(3):870-8. PubMed ID: 15919106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regulation of matrix-degrading enzymes in gynecologic cancer tissues and cells].
    Kikkawa F
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):618-22. PubMed ID: 8808829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation.
    Stahtea XN; Roussidis AE; Kanakis I; Tzanakakis GN; Chalkiadakis G; Mavroudis D; Kletsas D; Karamanos NK
    Int J Cancer; 2007 Dec; 121(12):2808-14. PubMed ID: 17721919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation.
    Zucker S; Mirza H; Conner CE; Lorenz AF; Drews MH; Bahou WF; Jesty J
    Int J Cancer; 1998 Mar; 75(5):780-6. PubMed ID: 9495249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.